文献速递类风湿关节炎

类风湿关节炎女性妊娠结局与疾病活动度及抗风湿治疗策略的关系:来自瑞典和丹麦的匹配队列研究

Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

RA妊娠早产(PTB)和小于胎龄儿(SGA)的校正比值比(aOR)均升高,妊娠期DAS28-CRP≥4.1者风险更高;妊娠期口服糖皮质激素与PTB的aOR为2.11(0.94-4.74),生物制剂为1.38(0.66-2.89)。作者认为妊娠期疾病活动度而非治疗似乎是RA中PTB和SGA最重要的危险因素。

要点

  • RA妊娠较对照妊娠早产aOR 1.92(1.56-2.35)、SGA aOR 1.93(1.45-2.57)。
  • 妊娠期DAS28-CRP≥4.1 vs <3.2者早产aOR 3.38(1.52-7.55)、SGA aOR 3.90(1.46-10.4)。
  • 妊娠期口服糖皮质激素与早产aOR 2.11(0.94-4.74),生物制剂为1.38(0.66-2.89)。

核心结论

  • 妊娠期疾病活动度而非治疗似乎是RA中早产和SGA最重要的危险因素。
  • 作者认为RA女性妊娠期应仔细监测,尤其存在中高疾病活动度和/或接受广泛抗风湿治疗者。

研究设计与样本

  • 链接瑞典SRQ和丹麦DANBIO临床风湿病登记与医疗出生登记的前瞻性临床登记匹配队列研究。
  • 通过临床风湿病登记和处方药登记识别妊娠前9个月及妊娠期疾病活动度(DAS28、CRP、HAQ评分)和抗风湿治疗。
  • 采用逻辑回归估计早产和SGA的aOR及95%CI,并按妊娠前后疾病活动度和抗风湿治疗分层,校正母亲特征。

主要发现

  • RA妊娠 vs 对照妊娠:早产aOR 1.92(1.56-2.35),SGA aOR 1.93(1.45-2.57)。
  • RA妊娠中妊娠期DAS28-CRP≥4.1 vs <3.2:早产aOR 3.38(1.52-7.55),SGA aOR 3.90(1.46-10.4)。
  • RA妊娠中妊娠期口服糖皮质激素(是/否)与早产aOR 2.11(0.94-4.74)相关。
  • RA妊娠中妊娠期生物制剂(是/否)与早产aOR 1.38(0.66-2.89)相关。
  • 妊娠前包含生物制剂的联合治疗是早产和SGA风险增加的标志。

关键数值与推荐

  • RA妊娠 vs 对照妊娠早产aOR 1.92(1.56-2.35)、SGA aOR 1.93(1.45-2.57)。
  • 妊娠期DAS28-CRP≥4.1 vs <3.2的RA妊娠早产aOR 3.38(1.52-7.55)、SGA aOR 3.90(1.46-10.4)。
  • 妊娠期口服糖皮质激素(是/否)早产aOR 2.11(0.94-4.74),生物制剂(是/否)早产aOR 1.38(0.66-2.89)。

临床怎么用

  • 作者认为RA女性妊娠期应仔细监测,尤其存在中高疾病活动度和/或接受广泛抗风湿治疗者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the association of maternal RA to pregnancy outcomes, especially preterm birth (PTB) and small for gestational age (SGA), in relation to disease activity and anti-rheumatic treatment before and during pregnancy. METHODS: By linking prospective clinical rheumatology registers (CRR) in Sweden (the Swedish Rheumatology Quality Register, SRQ) and Denmark (the Danish clinical quality register, DANBIO) with medical birth registers, we identified 1739 RA-pregnancies and 17 390 control-pregnancies (matched 1:10 on maternal age, birth year, parity) with delivery 2006-18. Disease activity (DAS28, CRP, HAQ score) and anti-rheumatic treatment 9 months before and during pregnancy were identified through CRR and prescribed drug registers. Using logistic regression, we estimated adjusted odds ratios (aOR) with 95% CI for PTB and SGA overall and stratified by disease activity and anti-rheumatic treatment before and during pregnancy, adjusting for maternal characteristics. RESULTS: We found increased aOR of PTB [1.92 (1.56-2.35)] and SGA [1.93 (1.45-2.57)] in RA-pregnancies vs control-pregnancies. For RA-pregnancies with DAS28-CRP ≥4.1 vs <3.2 during pregnancy, aOR was 3.38 (1.52-7.55) for PTB and 3.90 (1.46-10.4) for SGA. Use of oral CS (yes/no) during pregnancy resulted in an aOR of 2.11 (0.94-4.74) for PTB. The corresponding figure for biologics was 1.38 (0.66-2.89). Combination therapy, including biologics before pregnancy, was a marker of increased risk of both PTB and SGA. CONCLUSION: During pregnancy, disease activity rather than treatment seems to be the most important risk factor for PTB and SGA in RA. Women with RA should be carefully monitored during pregnancy, especially if they have moderate to high disease activity or/and are treated with extensive anti-rheumatic treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hellgren K, Secher AE, Glintborg B, et al. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology (Oxford). 2022. PMID: 34864891. doi:10.1093/rheumatology/keab894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。